Issam Awad to Hemangioma, Cavernous, Central Nervous System
This is a "connection" page, showing publications Issam Awad has written about Hemangioma, Cavernous, Central Nervous System.
Connection Strength
20.718
-
Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
Score: 0.770
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
Score: 0.767
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
Score: 0.767
-
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
Score: 0.734
-
Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
Score: 0.711
-
Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
Score: 0.681
-
Commentary: Feasibility and Morbidity of Magnetic Resonance Imaging-Guided Stereotactic Laser Ablation of Deep Cerebral Cavernous Malformations: A Report of 4 Cases. Neurosurgery. 2021 09 15; 89(4):E207-E208.
Score: 0.656
-
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
Score: 0.655
-
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
Score: 0.630
-
Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
Score: 0.628
-
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
Score: 0.494
-
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
Score: 0.493
-
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
Score: 0.470
-
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
Score: 0.460
-
Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods. 2016 09 15; 271:14-24.
Score: 0.456
-
B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. J Neuroimmune Pharmacol. 2016 06; 11(2):369-77.
Score: 0.451
-
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
Score: 0.447
-
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
Score: 0.445
-
Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
Score: 0.422
-
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med. 2015 Mar; 17(3):188-196.
Score: 0.401
-
Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. J Neuroimmunol. 2014 Jul 15; 272(1-2):67-75.
Score: 0.394
-
Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. Stroke. 2014 Feb; 45(2):598-601.
Score: 0.382
-
Cavernous malformations. J Neurosurg. 2012 Jan; 116(1):119-20; discussion 121.
Score: 0.329
-
Fatal "hypertensive" intracerebral hemorrhage associated with a cerebral cavernous angioma: case report. Acta Neurochir (Wien). 2011 Feb; 153(2):421-3.
Score: 0.306
-
Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus. 2010 Sep; 29(3):E4.
Score: 0.305
-
Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg Focus. 2010 Sep; 29(3):E6.
Score: 0.305
-
Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions. Neurosurgery. 2008 Oct; 63(4):782-9; discussion 789.
Score: 0.267
-
Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008 Oct; 63(4):790-7; discussion 797-8.
Score: 0.267
-
Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg. 2007 Nov; 107(5):1023-6.
Score: 0.251
-
Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery. 2006 Dec; 59(6):1278-84; discussion 1284-5.
Score: 0.235
-
Cerebral cavernous malformations: clinical insights from genetic studies. Neurosurg Focus. 2006 Jul 15; 21(1):e1.
Score: 0.229
-
Cerebral cavernous malformations and epilepsy. Neurosurg Focus. 2006 Jul 15; 21(1):e7.
Score: 0.229
-
Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol. 2005 Apr; 63(4):319-28; discussion 328.
Score: 0.210
-
Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005 Apr; 36(4):872-4.
Score: 0.208
-
Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: case report. Neurosurgery. 2004 Dec; 55(6):1431.
Score: 0.205
-
Antithrombotic Therapy in Cerebral Cavernous Malformations: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. J Am Heart Assoc. 2024 Mar 19; 13(6):e032910.
Score: 0.195
-
Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
Score: 0.190
-
mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023 11; 54(11):2906-2917.
Score: 0.189
-
ß1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 12; 36(12):e22629.
Score: 0.178
-
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
Score: 0.173
-
Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. Stroke. 2021 12; 52(12):3829-3838.
Score: 0.164
-
Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
Score: 0.162
-
Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. 2021 06 25; 129(1):195-215.
Score: 0.161
-
Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations. Elife. 2021 05 20; 10.
Score: 0.160
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
Score: 0.160
-
Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
Score: 0.154
-
Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
Score: 0.151
-
Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
Score: 0.150
-
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
Score: 0.149
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2020 Apr 03; 134(3):1147-1154.
Score: 0.148
-
Stereotactic laser interstitial thermal therapy for epilepsy associated with solitary and multiple cerebral cavernous malformations. Neurosurg Focus. 2020 04 01; 48(4):E12.
Score: 0.148
-
Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
Score: 0.146
-
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
Score: 0.145
-
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
Score: 0.145
-
Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
Score: 0.142
-
A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis. Nat Commun. 2019 04 17; 10(1):1791.
Score: 0.139
-
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
Score: 0.138
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
Score: 0.137
-
Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
Score: 0.135
-
The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB J. 2019 02; 33(2):2132-2143.
Score: 0.133
-
Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
Score: 0.131
-
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
Score: 0.130
-
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
Score: 0.125
-
Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
Score: 0.121
-
Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
Score: 0.112
-
Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping. Invest Radiol. 2014 Jul; 49(7):498-504.
Score: 0.099
-
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet. 2014 Aug 15; 23(16):4357-70.
Score: 0.098
-
Magnetic resonance imaging evaluation of cerebral cavernous malformations with susceptibility-weighted imaging. Neurosurgery. 2011 Mar; 68(3):641-7; discussion 647-8.
Score: 0.079
-
A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011 Jan 15; 20(2):211-22.
Score: 0.077
-
Brainstem cavernous malformations. Neurosurgery. 2009 May; 64(5):E805-18; discussion E818.
Score: 0.070
-
What genes can teach us about human cerebrovascular malformations. Clin Neurosurg. 2004; 51:140-52.
Score: 0.048
-
Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery. 2000 Jun; 46(6):1454-9.
Score: 0.037
-
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12; 207(4):881-96.
Score: 0.018
-
Biology of vascular malformations of the brain. Stroke. 2009 Dec; 40(12):e694-702.
Score: 0.018